bluuebunny/crossref_metadata_2025_split huggingface dataset:
A comparison between invasive and noninvasive measurement of the Hypotension Prediction Index
Authors: Rellum Santino R. , Kho Eline , Schenk Jimmy , van der Ster Björn J.P. , Vlaar Alexander P.J. , Veelo Denise P. 
Published: October 2024

BACKGROUND
Clinical trials and validation studies demonstrate promising hypotension prediction capability by the Hypotension Prediction Index (HPI). Most studies that evaluate HPI derive it from invasive blood pressure readings, but a direct comparison with the noninvasive alternative remains undetermined. Such a comparison could provide valuable insights for clinicians in deciding between invasive and noninvasive monitoring strategies.

OBJECTIVES
Evaluating predictive differences between HPI when obtained through noninvasive versus invasive blood pressure monitoring.

DESIGN
Post hoc analysis of a prospective observational study conducted between 2018 and 2020.

SETTING
Single-centre study conducted in an academic hospital in the Netherlands.

PATIENTS
Adult noncardiac surgery patients scheduled for over 2 h long elective procedures. After obtaining informed consent, 91 out of the 105 patients had sufficient data for analysis.

MAIN OUTCOME MEASURES
The primary outcome was the difference in area under the receiver-operating characteristics (ROC) curve (AUC) obtained for HPI predictions between the two datasets. Additionally, difference in time-to-event estimations were calculated.

RESULTS
AUC (95% confidence interval (CI)) results revealed a nonsignificant difference between invasive and noninvasive HPI, with areas of 94.2% (90.5 to 96.8) and 95.3% (90.4 to 98.2), respectively with an estimated difference of 1.1 (−3.9 to 6.1)%; P = 0.673. However, noninvasive HPI demonstrated significantly longer time-to-event estimations for higher HPI values.

CONCLUSION
Noninvasive HPI is reliably accessible to clinicians during noncardiac surgery, showing comparable accuracy in HPI probabilities and the potential for additional response time.

TRIAL REGISTRATION
Clinicaltrials.gov (NCT03795831) https://clinicaltrials.gov/study/NCT03795831
Recurrence and Risk Factors of Giant Cell Tumors in Hand Bones: A Systematic Review
Authors: Berger Ori , Mendelson Mor , Goren David , Andrakhanov Andrey , Talisman Ran 
Published: October 2024

Background:
Giant cell tumor of bone (GCTB) is a locally aggressive tumor that may affect the bones of the hand and rarely causes pulmonary metastasis. It exhibits a variable recurrence rate after surgical interventions, which presents challenges in its management. This systematic review aims to delineate recurrence rates and identify risk factors for GCTB in the hand.

Methods:
We conducted a systematic literature search in April 2024, following PRISMA guidelines, on PubMed and TDNet for studies reporting postsurgical recurrence of GCTB in the hand. Cohort and case-control studies provided recurrence rates, whereas case reports and series were utilized to identify risk factors, compensating for the sparse data in the primary studies. We used descriptive statistics, χ2 tests, and logistic regression to analyze demographics, lesion characteristics, treatments, and outcomes.

Results:
We reviewed 13 cohort and case-control studies involving 244 patients, finding an overall recurrence rate of 19.57%. Curettage was associated with higher recurrence rates compared with other surgical methods. After additional review of case reports, a limited range of motion in patients emerged as a significant protective factor against recurrence, suggesting potential benefits in surgical management and outcome prediction.

Conclusions:
The significant recurrence rate associated with curettage highlights the need for alternative surgical strategies in GCTB management of the hand. The protective role of limited ROM underscores the importance of thorough preoperative assessments to optimize surgical approaches and enhance patient outcomes.
Factors for Consideration for Hematological Cancer Patients When Planning for Place of Death
Authors: Campbell Karen , Stoddart Kathleen 
Published: October 2024

Background
Planning for place of death is considered troublesome for patients with hematological cancer. Qualitative studies have focused on healthcare professionals and caregivers. To date, no study has been conducted from the patient’s perspective of planning for place of death in the last year of life.

Objective
To develop an understanding of how patients with hematological cancer experience planning for place of death in their last year of life.

Methods
The study used constructivist grounded theory, semistructured interviews, a constant comparison technique, and memoing to collect and analyze data. The 21 participants were attending a cancer center, cancer unit, or hospice in the United Kingdom.

Results
This article describes one core category, factors influencing planning for death, within the incurable hematology cancer illness trajectory through the following 2 subcategories: personal factors—driving away, developing a legacy, designing a death plan, and disease determining; and environmental factors—dependent determination, displacement of the home, and discernment of services.

Conclusion
This critical study illustrates that planning for place of death is complex and multifaceted in conjunction with an unpredictable incurable illness trajectory.

Implications for Practice
Preferences for the place of death will change over time depending on the illness trajectory experienced by patients with hematological cancer and the level of physical and emotional energy and independence afforded to discuss and plan.
Validation of a Simplified Laboratory-Based HCV Clearance Definition Using New York City Hepatitis C Program and Surveillance Data
Authors: Hwang Christina S. , Montgomery Martha P. , Diaz Munoz Diana I. , Yin Shaoman , Teshale Eyasu H. , Bocour Angelica 
Published: October 2024

Context:
Laboratory-based hepatitis C virus (HCV) clearance cascades are an important tool for health departments to track progress toward HCV elimination, but a laboratory-based definition of HCV clearance has not yet been validated.

Objective:
To compare agreement between a laboratory-based HCV clearance definition with a clinical cure definition.

Design:
Observational.

Setting:
New York City Department of Health and Mental Hygiene HCV surveillance system data and New York City hepatitis C linkage-to-care program data.

Participants:
Linkage-to-care program participants who were diagnosed with hepatitis C and enrolled in the linkage-to-care program from July 1, 2016, through June 30, 2020.

Main Outcome Measure:
Percent agreement between a laboratory-based HCV clearance definition (surveillance system) and a clinical cure definition (program data).

Results:
Among 591 program participants with known treatment outcome, the laboratory-based HCV clearance definition and clinical cure definition were concordant in 573 cases (97%).

Conclusions:
A laboratory-based HCV clearance definition based on public health surveillance data can be a reliable source for monitoring HCV elimination.
Associations Between Sexual Orientation Dimensions and Cardiometabolic Diseases: Data From the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III)
Authors: Crawford Christopher A. , Carson Ian W. , Polanka Brittanny M. , Williams Michelle K. , Higgins Alexis B. , Schuiling Matthew D. , Stewart Jesse C. 
Published: October 2024

ABSTRACT

Objective
Sexual orientation can be measured across identity, attraction, and behavior. Sexual minorities are at increased risk of cardiovascular disease (CVD) and diabetes; however, it is not known whether cardiometabolic disease risk varies across these dimensions.

Methods
We analyzed cross-sectional data from 36,309 adults who participated in the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III; 2012–2013). Participants were categorized as heterosexual (reference), lesbian/gay, or bisexual across identity, attraction, and behavior using structured clinical interview data. Prevalent CVD (myocardial infarction, stroke, angina, or arteriosclerosis) and diabetes were assessed by self-report.

Results
Demographics (age, sex, race/ethnicity, education, and income) adjusted logistic regression models revealed bisexual behavior (i.e., people reporting sexual activity with both man- and woman-identifying individuals), but not lesbian/gay behavior (i.e., people reporting sexual activity exclusively with same-sex individuals), was associated with an increased odds of prevalent CVD (OR = 1.44, 95% CI = 1.08–1.91, p = .013) and prevalent diabetes (OR = 1.39, 95% CI = 1.09–1.77, p = .007). Contrastingly, sexual minority identity (i.e., self-concept) and attraction (i.e., one’s sexual/romantic feelings) were not associated with prevalent CVD or diabetes.

Conclusions
Our results in a nationally representative sample indicate that the sexual orientation dimension of behavior is linked with prevalent CVD and diabetes. This finding suggests that assessing multiple sexual orientation dimensions may aid in identifying sexual minority subgroups in greatest need of cardiometabolic disease prevention efforts. Although mechanisms such as stigma and minority stress have been proposed, future studies are required to elucidate mechanisms underlying the bisexual behavior-cardiometabolic disease relationship.
Birth outcomes following bictegravir exposure during pregnancy
Authors: Olivero Rosemary , Williams Paige L. , Sawyer George , Yee Lynn M. , Patel Kunjal , Hernandez-Diaz Sonia , Powis Kathleen , Paul Mary , Chadwick Ellen G. ,   for the Pediatric HIV/AIDS Cohort Study and the HOPE study
Published: October 2024

Objective:
Bictegravir is increasingly prescribed as a co-formulated tablet with tenofovir alafenamide and emtricitabine to pregnant persons with HIV (PWH) despite limited pregnancy and birth outcome data. We sought to provide birth outcome data following exposure to bictegravir during pregnancy.

Design:
We conducted a descriptive analysis of infants born to pregnant PWH 18–45 years of age enrolled in at least one Pediatric HIV/AIDS Cohort Study (PHACS)-affiliated study who received bictegravir for ≥7 days during pregnancy and completed follow-up through delivery.

Methods:
The outcomes of interest were gestational age at birth, preterm birth (<37 weeks’ gestation), gestational-age adjusted birth weight (BWZ) and length (BLZ) Z-scores, small for gestational age (SGA, birthweight <10th percentile), congenital anomalies, neonatal deaths in the first 28 days of life, and infant HIV status.

Results:
A total of 177 infants born to 170 unique PWH were exposed to bictegravir for ≥7 days during gestation; 55% were exposed to bictegravir from the time of conception. Median gestational age at birth was 38.1 weeks. The prevalence of preterm birth was 15.8% and SGA was 9.3%. Mean BWZ and BLZ were −0.48 and 0.03. No neonatal deaths or perinatal HIV transmissions were reported. Among 126 infants exposed to first-trimester bictegravir, 7 (5.6%) had major congenital anomalies with no specific pattern suggestive of a syndrome.

Conclusions:
These findings provide preliminary data without significant safety concerns for fetal bictegravir exposure in this United States cohort. Comparative data and continued surveillance of outcomes among infants exposed to bictegravir during gestation are warranted.
Comparing Three-dimensional Radiologic Outcomes Between Early Versus Late Secondary Alveolar Bone Grafting
Authors: Lu Xuanyu , Roohani Idean , Manasyan Artur , Stanton Eloise W. , Youn Simon , Hammoudeh Jeffrey A. , Urata Mark M. , Magee William P. , Allareddy Veerasathpurush , Yen Stephen L. 
Published: October 2024

Secondary alveolar bone grafting (SABG) during mixed dentition is the standard of care for patients with complete cleft of lip and palate. Early SABG (E-SABG; 4 to 7 y) occurs before the eruption of lateral incisors, whereas late SABG (L-SABG; 8 to 12 y) occurs before the eruption of maxillary permanent canines. This study compares outcomes of E-SABG versus L-SABG among patients with unilateral cleft of lip and palate (UCLP). A prospective cohort study was conducted evaluating nonsyndromic patients with UCLP who underwent SABG from April 2018 to January 2020, 48 consecutive patients with UCLP were included. Preoperative and 6 to 10-month postoperative cone beam computed tomography imaging were obtained to assess graft and periodontal outcomes. Among 48 patients with UCLP, of which 21 were in the E-SABG group (6.9 ± 1.1 y), and 28 were in the L-SABG cohort (10.4 ± 1.6 y). The initial alveolar cleft width is significantly smaller in the E-SABG cohort compared with the L-SABG cohort (5.1 ± 1.5 versus 6.5 ± 2.0 mm, P = 0.008). Compared with the L-SABG cohort, the E-SABG cohort had higher rates of bony bridge formation (77.3% versus 65.4%, P= 0.367), thicker bony bridges (5.7 ± 2.1 versus 3.9 ± 1.5 mm, P= 0.004), lower Bergland scores [1.5 (interquartile range: 1 to 2) versus 2.25 (interquartile range: 1.5 to 3.5), P= 0.026], and greater alveolar bone coverage (79.8 ± 16.7% versus 67.9 ± 18.1%, 0.024). The authors' findings suggest that patients who undergo E-SABG at ∼7 years may have better graft outcomes and benefits to the periodontal bone support on cleft-adjacent incisor compared with L-SABG at 11 years.
Long-Term Nose Evaluation After Treatment of Bilateral Cleft Lip Using the Spina Technique
Authors: da Silva Freitas Renato , Tascheck Eduardo Matheus , Adania Eduardo Takemura , Urano Willian Eiki Minowa 
Published: October 2024

Introduction:
Bilateral cleft lip (BCL) repair is a challenge due to anatomic and functional distortions, worse than unilateral cleft. With regard to the nose, BCL can result in certain characteristics, such as a short columella, a flattened and widened tip, and horizontally oriented nostrils. Lip and nose treatment is advocated by some surgeons to achieve a better outcome. One of the techniques used to treat this condition is the one recommended by Victor Spina, in a complex protocol involving more than one surgical procedure and long-term follow-up. The aim of this study is to evaluate the growth of the nose in patients treated using the Spina technique.

Materials and Methods:
This was a retrospective and analytical study of the medical records of patients who were treated using the Spina technique at the Assistance Center for Cleft Lip and Palate (CAIF) at Hospital do Trabalhador in Curitiba, Brazil. Anthropometric measurements of interalar distance and nose tip projection were made from frontal and submental photographs taken at three moments: pre-first surgery, pre-definitive surgery, and late follow-up. Furthermore, other analyzed parameters were: sex, date of birth, age at time of surgery, and late follow-up. With these data, a comparison of nose growth was made between patients with BCL and a population without craniofacial anomalies observed in a study by FARKAS et al (1992). The comparison also took sex and age variables into account.

Results:
Regarding the interalar distance measurements, both sexes showed a widening of the nose before starting treatment. This widening was maintained throughout follow-up. The growth curve, in turn, remained similar among males, with an average growth rate of only 3.2% higher in patients with BCL. Among females, the difference was one of 16.92%. In terms of nasal tip projection, there was an average increase of 1.12 cm (86.15%) in males and 0.69 cm (57.02%) in females.

Conclusion:
It was possible to notice a nasal growth rate in those with BCL similar to the normal pattern and a significant improvement in nasal tip projection in male patients. However, with regard to the data of both sexes, but especially females, the low number of patients jeopardized the significance of the results.
The Evaluation of Facial Artery Position in Related to Soft Tissue Pogonion and Soft Tissue Gonion: A Cadaver Study
Authors: Tabrizi Reza , Sharifzadeh Hadi , Baniameri Sahar , Peacock Zachary S. 
Published: October 2024

This anatomic study was designed to assess the position of the facial artery concerning the soft tissue landmarks, pogonion (Pog)and Gonion (Go). Sixty freshly frozen cadavers were used in this study. On the right side, the mean distance between the facial artery and Pog was 7.05±0.66 cm. The mean distance between the facial artery and Go was 3.34±0.36 cm. The results indicated that the facial artery was 32.32%±2.05 of a mandibular length to Go and 67.78%±2.05 Pog. On the left side, the mean distance between the facial artery and Pog was 7.10±0.65 cm. The mean distance between the facial artery and Go was 3.23±0.34 cm. The results indicated that the facial artery was 31.30±2% of the mandibular length at Go and 68.71±2% at Pog. The ratio of the facial artery distance to Pog and Go did not correlate with the mandibular length (P>0.05). However, the distance between the facial artery, Pog, and Go correlated with mandibular length. (P<0.001).
The ratio of the cross-point of the facial artery with the mandibular border to the length of the mandible about Go and the Pog was generally found to be independent of mandibular length.
Yoonia algicola sp. nov., Yoonia rhodophyticola sp. nov. and Yoonia phaeophyticola sp. nov., isolated from marine algae
Authors: Han Dong Min , Jeon Ji Hoon , Jin Myeong Seo , Choi Dae Gyu , Kim Jeong Min , Bayburt Hülya , Choi Byeong Jun , Jeon Che Ok 
Published: October 2024

Three Gram-stain-negative, strictly aerobic, non-motile, oxidase- and catalase-positive, short-rod-shaped bacteria, designated as strains G8-12T, SS1-5T and BS5-3T, were isolated from marine algae in South Korea. Strain G8-12T exhibited optimal growth at 20–25 °C, pH 8.0 and 2.0–2.5% (w/v) NaCl, while strains SS1-5T and BS5-3T grew optimally at 25 °C, pH 7.0 and 1.5% NaCl. All strains contained ubiquinone-10 as the sole respiratory quinone, with phosphatidylglycerol and phosphatidylcholine as major polar lipids, and C18 : 1
ω7c and C16 : 0 as major fatty acids (>5 %); C18 : 1
ω7c 11-methyl and C18 : 1 2-OH were additionally identified as major fatty acids in strain SS1-5T. The genomic DNA G+C contents were 57.0, 58.3 and 56.4% for strains G8-12T, SS1-5T and BS5-3T, respectively. Strains G8-12T, SS1-5T and BS5-3T exhibited less than 74.8% average nucleotide identity (ANI) and 19.7% digital DNA–DNA hybridization (dDDH) values with each other, indicating that they represent different species. Phylogenetic analyses based on both 16S rRNA gene and genome sequences revealed that strains G8-12T, SS1-5T and BS5-3T form distinct phylogenetic lineages within the genus Yoonia. Relative to other closely related Yoonia species, these strains exhibited ANI and dDDH values below 83.5 and 26.9%, respectively, suggesting that they constitute novel species within the genus Yoonia. Based on their phenotypic, chemotaxonomic and phylogenetic characteristics, strains G8-12T, SS1-5T and BS5-3T represent three novel species of the genus Yoonia, for which the names Yoonia algicola sp. nov. (G8-12T=KACC 22753T=JCM 35790T), Yoonia rhodophyticola sp. nov. (SS1-5T=KACC 22649T=JCM 35753T) and Yoonia phaeophyticola sp. nov. (BS5-3T=KACC 22648T=JCM 35751T) are proposed, respectively.
Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer
Authors: Sands Jacob M. , Champiat Stéphane , Hummel Horst-Dieter , Paulson Kelly G. , Borghaei Hossein , Alvarez Jean Bustamante , Carbone David P. , Carlisle Jennifer W. , Choudhury Noura J. , Clarke Jeffrey M. , Gadgeel Shirish M. , Izumi Hiroki , Navarro Alejandro , Lau Sally C. M. , Lammers Philip E. , Huang Shuang , Hamidi Ali , Mukherjee Sujoy , Owonikoko Taofeek K. 
Published: October 2024

AbstractTarlatamab is a bispecific T-cell engager (BiTE®) immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients with previously treated small cell lung cancer (SCLC), tarlatamab 10 mg every 2 weeks achieved durable responses and encouraging survival outcomes. Analyses of updated safety data from the DeLLphi-301 trial showed that the most common treatment-emergent adverse events (TEAEs) were cytokine release syndrome (CRS; 53%), pyrexia (38%), decreased appetite (36%), dysgeusia (32%), and anemia (30%). CRS was mostly grade 1 or 2 in severity, occurred primarily after the first or second tarlatamab dose, and was managed with supportive care, which included administration of antipyretics (e.g., acetaminophen), intravenous hydration and/or glucocorticoids. Other TEAEs of interest included neutropenia (16%) and immune-effector cell-associated neurotoxicity syndrome and associated neurologic events (10%). Given that tarlatamab is the first T-cell engager approved for the treatment of SCLC, raising awareness regarding the monitoring and management of tarlatamab-associated adverse events is essential. Here, we describe the timing, occurrence, and duration of these AEs and review the management and risk mitigation strategies used by clinical investigators during the DeLLphi-301 trial.
CFTR structures bound to ETI components predict rare mutation response to modulator combinations
Authors: Stanleigh Noemie , Gur Michal , Shteinberg Michal , Weiss Aryeh , Sebbag-Sznajder Naama , Duran Deborah , Grunewald Myriam , Birimberg-Schwartz Liron , Bar-Yoseph Ronen , Beekman Jeffrey M. , Kerem Eitan , Wilschanski Michael , Kerem Batsheva 
Published: October 2024

AbstractBackgroundCFTR protein structures bound to each of Elexacaftor/Tezacaftor/Ivacaftor (ETI) were recently established. We aimed to use this data to predict and assess responses to ETI and each of its components in intestinal organoids derived from patients carrying rare CFTR mutations, not yet approved for ETI, based on their mutation location within the CFTR structure.MethodsOrganoids were generated from six patients carrying the Q1100P and/or K163E alleles, not receiving ETI. Measurements of the response to ETI or combination of its components were performed in 3D-organoids by forskolin-induced swelling (FIS) and in 2D-monolayers by short-circuit currents (Isc). Based on these results, patients initiated off-label ETI treatment. Clinical data before and after treatment were collected.ResultsVX-445 binds amino acids flanking Q1100P and VX-661 binds near the TM2-ICL1 boundary, where K163E is located. Thus, each modulator was predicted to contribute to the correction of one mutation. Functional measurements (FIS and Isc) indeed showed that Q1100P responded to VX-445 alone, and K163E to VX-661 alone. Unexpectedly, VX-445 had a dramatic effect on K163E function. Both mutations achieved clinically significant CFTR activity levels with VX-661+VX-445, without benefit from VX-770. Following these results ETI was initiated, resulting in significant and sustained clinical improvements, in all patients, in lung function (FEV1, LCI), BMI and sweat chloride.ConclusionThese results suggest that our structural approach can help predict response to the available modulators in patients carrying rare CFTR mutations. Furthermore, this approach allows for patient-specific optimization of modulator combinations, minimizing unnecessary exposure to ineffective treatments.